Related references
Note: Only part of the references are listed.The pathogenesis of the bone disease of multiple myeloma
Claire M. Edwards et al.
BONE (2008)
HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma
Ramadevi Nimmanapalli et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma
Martin Kaiser et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
I. Breitkreutz et al.
LEUKEMIA (2008)
Treatment strategies for bone disease
G. D. Roodman
BONE MARROW TRANSPLANTATION (2007)
Pathologic fractures correlate with reduced survival in patients with malignant bone disease
Fred Saad et al.
CANCER (2007)
Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma
Shuji Ozaki et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2007)
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients
Nicola Giuliani et al.
BLOOD (2007)
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo
Shmuel Yaccoby et al.
BLOOD (2007)
Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: A role for vascular endothelial cell growth factor and osteopontin
Ybichi Tanaka et al.
CLINICAL CANCER RESEARCH (2007)
Multiple myeloma bone disease: pathophysiology of osteoblast inhibition
Nicola Giuliani et al.
BLOOD (2006)
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma
Evangelos Terpos et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
MIP-1α (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma
Esther Masih-Khan et al.
BLOOD (2006)
Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation
Marianna C. Politou et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment
Ulrike Heider et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2006)
Thalidomide and lenalidomide in the treatment of multiple myeloma
Shaji Kumar et al.
EUROPEAN JOURNAL OF CANCER (2006)
Proteasome inhibition in multiple myeloma
Martin Kropff et al.
EUROPEAN JOURNAL OF CANCER (2006)
Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation
Aaron N. Nguyen et al.
EXPERIMENTAL CELL RESEARCH (2006)
Interleukin-7 influences osteoclast function in vivo but is not a critical factor in ovariectomy-induced bone loss
SK Lee et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1
G Anderson et al.
BLOOD (2006)
Wnt signalling in osteoblasts regulates expression of the receptor activator of NFκB ligand and inhibits osteoclastogenesis in vitro
GJ Spencer et al.
JOURNAL OF CELL SCIENCE (2006)
A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer
JJ Body et al.
CLINICAL CANCER RESEARCH (2006)
Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2
T Oshima et al.
BLOOD (2005)
Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma
M Zangari et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation
N Giuliani et al.
BLOOD (2005)
IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma
LA Ehrlich et al.
BLOOD (2005)
Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation
DA Glass et al.
DEVELOPMENTAL CELL (2005)
Fracture risk with multiple myeloma: A population-based study
LJ Melton et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Minireview: Transcriptional regulation in development of bone
T Kobayashi et al.
ENDOCRINOLOGY (2005)
Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1α and MIP-1β correlates with lytic bone lesions in patients with multiple myeloma
T Hashimoto et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells
JW Lee et al.
BLOOD (2004)
Pathogenesis of myeloma bone disease
GD Roodman
BLOOD CELLS MOLECULES AND DISEASES (2004)
Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells
F Silvestris et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Wnt signaling in osteoblasts and bone diseases
JJ Westendorf et al.
GENE (2004)
Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion
M Abe et al.
BLOOD (2004)
Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines
Y Nefedova et al.
BLOOD (2004)
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma
E Tian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Serum levels of macrophage inflammatory protein-1 alpha (MIP-1α) correlate with the extent of bone disease and survival in patients with multiple myeloma
E Terpos et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
New insights in myeloma-induced osteolysis
S Barillé-Nion et al.
LEUKEMIA & LYMPHOMA (2003)
Soluble receptor activator of nuclear factor κB ligand-osteoprotegerin ratio predicts survival in multiple myeloma:: proposal for a novel prognostic index
E Terpos et al.
BLOOD (2003)
Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease
F Magrangeas et al.
BLOOD (2003)
Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro
IR Garrett et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Osteoclast differentiation and activation
WJ Boyle et al.
NATURE (2003)
Regulation of the osteoblast-specific transcription factor, runx2: Responsiveness to multiple signal transduction pathways
RT Franceschi et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2003)
IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor κB ligand and tumor necrosis factor a from T cells
G Toraldo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity
S Yaccoby et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease
SJ Choi et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression
RN Pearse et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Macrophage inflammatory protein-1α is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor κB ligand
JH Han et al.
BLOOD (2001)
The osteoblast-specific transcription factor Cbfa1 contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function
K Thirunavukkarasu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism
J Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
